1 Green Flag and 1 Red Flag for Bluebird Bio Stock
https://www.fool.com/investing/2023/12/23/1-green-flag-and-1-red-flag-for-bluebird-bio-stock/?source=iedfolrf0000001
Dec 23, 2023 - The stock has been in the news lately.
0
Passage Bio stock climbs 9% on dementia study, program update
https://seekingalpha.com/news/4048762-passage-bio-stock-climbs-on-dementia-study-program-update?source=feed_sector_healthcare
Dec 20, 2023 - Passage Bio (PASG) shares surged 9% on encouraging Phase 1/2 data for gene therapy candidate PBFT02 in treating FTD-GRN, a type of early onset dementia. Read more here.
0
bluebird bio announces proposed public offering of common stock
https://seekingalpha.com/news/4047685-bluebird-bio-announces-proposed-public-offering-of-common-stock?source=feed_sector_healthcare
Dec 18, 2023 - bluebird bio (BLUE) announces an underwritten public offering of $150M of its common stock, with proceeds to support gene therapies and general purposes.
0
Tourmaline Bio announces addition to NASDAQ Biotechnology Index
https://seekingalpha.com/news/4046988-tourmaline-bio-announces-addition-to-nasdaq-biotechnology-index?source=feed_sector_healthcare
Dec 15, 2023 - Tourmaline Bio (TRML) has been added to the NASDAQ Biotechnology Index, effective Dec.
0
Down 30% in a Week, What in the World Is Going On With Bluebird Bio Stock?
https://www.fool.com/investing/2023/12/15/down-30-in-a-week-what-in-the-world-is-going-on-wi/?source=iedfolrf0000001
Dec 15, 2023 - An expected big win is rapidly turning into a defeat.
0
bluebird bio gene therapy lovo-cel for sickle cell disease has $3.1M cost (updated)
https://seekingalpha.com/news/4044803-bluebird-bio-gains-fda-approval-gene-therapy-lovo-cell-sickle-cell-disease?source=feed_sector_healthcare
Dec 08, 2023 - The FDA approves bluebird bio's gene therapy for sickle cell disease, boosting shares by 7%. Read more here.
0
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?
https://www.zacks.com/stock/news/2194974/theravance-bio-tbph-up-2-5-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2194974
Dec 07, 2023 - Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
2seventy Bio gains amid push from activist investor Engine Capital (update)
https://seekingalpha.com/news/4043994-2seventy-bio-gains-amid-push-from-activist-investor-engine-capital?source=feed_sector_healthcare
Dec 06, 2023 - Activist investor Engine Capital calls for changes at cancer therapy developer 2seventy Bio, pushing for a board refresh and new CEO appointment.
0
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2192301
Dec 01, 2023 - Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
0
Gossamer Bio (GOSS) Investor Presentation - Slideshow
https://seekingalpha.com/article/4534275-gossamer-bio-goss-investor-presentation-slideshow?source=feed_sector_healthcare
Aug 14, 2022 -
0